Outlook Therapeutics Raises $18.4 Million, Boosts Cash Position

Outlook Therapeutics has secured $18.4 million in financing to support commercialization of its ophthalmic therapy LYTENAVA. The company expects to receive $17 million in net proceeds and has strengthened its liquidity position. LYTENAVA is approved in Europe and the UK for wet age-related macular degeneration and Outlook is pursuing US approval. The company has traded between $0.34 and $3.39 over the past year.